Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic Microsomes
Authors:
- Fabrizio D’espositoFDFabrizio D’esposito
- Robert J. EdwardsRERobert J. Edwards
- Iqbal RamzanIRIqbal Ramzan
- Michael MurrayMMMichael Murray
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 36 (12) , 2547-2555
Abstract
The atypical antipsychotic drug clozapine (CLZ) is effective in a substantial number of patients who exhibit treatment-resistance to conventional agents. CYP1A2 is generally considered to be the major enzyme involved in the biotransformation of CLZ to its N-demethylated (norCLZ) and N-oxygenated (CLZ N-oxide) metabolites in liver, but several studies have also implicated CYP3A4. The present study assessed the interplay between these cytochrome P450s (P450s) in CLZ biotransformation in a panel of hepatic microsomal fractions from 14 individuals. The relative activity of P450s 1A2 and 3A4 in microsomes was found to be a major determinant of the relative susceptibility of norCLZ formation to inhibition by the P450-selective inhibitors fluvoxamine and ketoconazole. In contrast, the activity of CYP3A4 alone was correlated with the susceptibility of CLZ N-oxide formation to inhibition by these agents. These findings suggest that both P450s may be dominant CLZ oxidases in patients and that the relative activities of these enzymes may determine clearance pathways. In vivo assessment of CYP1A2 and CYP3A4 activities, perhaps by phenotyping approaches, could assist the optimization of CLZ dosage and minimize pharmacokinetic interactions with coadministered drugs.Keywords
This publication has 35 references indexed in Scilit:
- Estimating the Size of the Effects of Co-Medications on Plasma Clozapine Concentrations using a Model that Controls for Clozapine Doses and Confounding VariablesPharmacopsychiatry, 2008
- Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic SteatosisThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotypePharmacogenetics and Genomics, 2006
- The effect of nefazodone on clozapine plasma concentrationsInternational Clinical Psychopharmacology, 1999
- Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake InhibitorsJournal of Clinical Psychopharmacology, 1998
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of ClozapineTherapeutic Drug Monitoring, 1994
- N‐desmethylclozapine: a clozapine metabolite that suppresses haemopoiesisBritish Journal of Haematology, 1994
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970